<?xml version="1.0" encoding="UTF-8"?>
<p>Be it the current pandemic caused by SARS-CoV-2 or Spanish influenza caused by H1N1, it has been suggested that the implementation of CP remarkably reduces the case fatality rate [
 <xref rid="RSOB200174C48" ref-type="bibr">48</xref>]. Moreover, the use of CP in other CoVs like SARS-CoV resulted in a reduction in the number of days that a severely sick patient was supposed to spend in the hospital [
 <xref rid="RSOB200174C49" ref-type="bibr">49</xref>,
 <xref rid="RSOB200174C50" ref-type="bibr">50</xref>]. Keeping in view the usage of mechanized ventilation systems during the avian influenza A (H5N1) and the 2009 pandemic of influenza A (H1N1), the implementation of CP therapy decreased the duration of invasive and obtrusive ventilation [
 <xref rid="RSOB200174C51" ref-type="bibr">51</xref>,
 <xref rid="RSOB200174C52" ref-type="bibr">52</xref>]. Presently, the administration of CP to COVID-19 patients has exhibited improvement in their clinical condition and a reduction of the viral load [
 <xref rid="RSOB200174C53" ref-type="bibr">53</xref>,
 <xref rid="RSOB200174C54" ref-type="bibr">54</xref>].
</p>
